Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Chinese Biotech Beigene Raises $903m In Hk's First Secondary Listing Under New Rules: Sources
Hedge Funds

Chinese Biotech Beigene Raises $903m In Hk's First Secondary Listing Under New Rules: Sources

by reuters.com posted 2months ago 14 views
* Deal is second under new rules for early-stage biotechs (Adds deal details, context): HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday. The listing comes as Hong Kong works to lure overseas-listed firms to conduct secondary share offerings in the financial hub. It is also the second listing under new rules for early-state drug developers.